ClinicalTrials.gg
CompletedNCT04606537Updated Dec 16, 2025

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

A Phase 1 interventional study of Itraconazole and Rifampin in Healthy and Drug Drug Interaction, sponsored by KBP Biosciences. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by KBP Biosciences · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Nov 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK of a single dose of KBP-5074 in healthy male and female subjects.

02

Conditions studied

  • Healthy
  • Drug Drug Interaction

Keywords

  • KBP5074
  • Healthy Subjects
  • itraconazole
  • rifampin
03

In context

Lead sponsor

KBP Biosciences is the lead sponsor of 12 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, of any race, between 18 and 60 years of age, inclusive, at screening.
  • between 18.0 and 32.0 kg/m2, inclusive, at screening.
  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any medical history, as determined by the investigator not appropriate to participate in this study.
  • Use of any drugs or substances known to be strong or moderate inhibitors or inducers of within 30 days prior to study drug administration. Medications will be reviewed by the medical monitor to determine acceptability for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)

    Drug: Itraconazole · Drug: KBP-5074

  • Experimental
    Cohort 2 (Effects of CYP3A4 induction on KBP-5074)

    Drug: Rifampin · Drug: KBP-5074

Interventions

  • DrugItraconazole

    200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.

  • DrugRifampin

    600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.

  • 0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter: Maximum observed concentration (Cmax)

    Maximum observed concentration (Cmax) - Plasma

    Time frame: Days 1 and 19 at predose (Cohort 1) and Days 1 and 21 at predose (Cohort 2) and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 240 hours postdose.

  2. Pharmacokinetic Parameter: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

    Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma

    Time frame: Days 1 and 19 at predose (Cohort 1) and Days 1 and 21 at predose (Cohort 2) and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 240 hours postdose.

  3. Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)

    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma

    Time frame: Days 1 and 19 at predose (Cohort 1) and Days 1 and 21 at predose (Cohort 2) and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 240 hours postdose.

07

Study locations

1 site
  • QPS Missouri
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Nov 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2020
First posted
Oct 28, 2020
StartActual
Oct 24, 2020
Primary completionActual
Nov 30, 2020
CompletionActual
Nov 30, 2020
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04606537
Lead sponsor
KBP Biosciences
Collaborators
Covance
Responsible party
Sponsor
First posted
Oct 28, 2020
Start date
Oct 24, 2020
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Last update
Dec 16, 2025

Study contacts

James McCabe
study director · KBP Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion